From: Transforming growth factor beta (TGF-β) in adolescent chronic fatigue syndrome
CFS patients (n = 120) | Healthy controls (n = 68) | p valuec | |||
---|---|---|---|---|---|
Background | |||||
Female gender Number, % | 88 | 73 | 46 | 68 | 0.563 |
Age (years) Mean, SD | 15.4 | 1.6 | 15.1 | 1.6 | 0.179 |
Body mass index (kg/m2) Mean, SD | 21.5 | 4.2 | 20.6 | 3.7 | 0.119 |
Disease duration (months) Median, range | 18 | 4–104 | n/a | ||
Adheres to the Fukuda criteria of CFSa Number, % | 88 | 73 | n/a | ||
Adheres to the Canada 2003-criteria of CFSb Number, % | 46 | 38 | n/a | ||
Immune, autonomic and neuroendocrine markers | |||||
Serum C-reactive protein (mg/l) Median, IQR | 0.43 | 0.96 | 0.35 | 0.46 | 0.049 |
Heart rate variability, LF power (abs) Median, IQR | 481 | 772 | 682 | 1514 | 0.015 |
Heart rate variability, HF power (abs) Median, IQR | 788 | 1835 | 1058 | 1837 | 0.070 |
Heart rate variability, LF/HF-ratio Median, IQR | 0.69 | 0.64 | 0.74 | 0.38 | 0.792 |
Plasma norepinephrine (pmol/l) Mean, SD | 1991 | 783 | 1483 | 422 | < 0.001 |
Plasma epinephrine (pmol/l) Median, IQR | 308 | 131 | 265 | 95 | 0.001 |
Plasma cortisol (nmol/l) Mean, SD | 367 | 143 | 351 | 150 | 0.460 |
Urine norepinephrine/creatinine ratio (nmol/mmol) Median, IQR | 12.3 | 5.8 | 10.8 | 5.8 | 0.102 |
Urine epinephrine/creatinine ratio (nmol/mmol) Median, IQR | 1.3 | 1.2 | 1.5 | 1.0 | 0.649 |
Urine cortisol/creatinine ratio (nmol/mmol) Median, IQR | 3.4 | 3.1 | 5.3 | 6.0 | 0.001 |
Clinical makers | |||||
Symptoms of post-exertional malaise (total score) Mean, SD | 4.0 | 1.0 | 1.4 | 0.5 | < 0.001 |
Inflammatory symptoms (total score) Mean, SD | 2.1 | 0.9 | 1.3 | 0.5 | < 0.001 |
Chalder Fatigue Questionnaire (total score) Mean, SD | 19.3 | 6.1 | 8.7 | 4.6 | < 0.001 |
Moods and Feelings Questionnaire (total score) Mean, SD | 17.4 | 10.0 | 6.4 | 7.8 | < 0.001 |
Spielberger state-trait anxiety questionnaire (trait subscore) Mean, SD | 43.2 | 8.9 | 32.3 | 7.2 | < 0.001 |
Steps per day (number) Mean, SD | 4662 | 2386 | 10,293 | 3716 | < 0.001 |